Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024 Feb 27;10(1):e004016.
doi: 10.1136/rmdopen-2023-004016.

Association between disease-modifying antirheumatic drugs for rheumatoid arthritis and risk of incident dementia: a systematic review with meta-analysis

Wenhui Xie  1 , Yue Hou  2 , Shiyu Xiao  3 , Xiaolin Zhang  2 , Zhuoli Zhang  4
Affiliations
Meta-Analysis

Association between disease-modifying antirheumatic drugs for rheumatoid arthritis and risk of incident dementia: a systematic review with meta-analysis

Wenhui Xie et al. RMD Open. .

Abstract

Background: Dysregulation of several inflammatory cytokines including tumour necrosis factor (TNF) in dementia patients has also been identified as a key factor in the pathogenesis of rheumatoid arthritis (RA). We aimed to investigate the association of disease-modifying antirheumatic drugs (DMARDs) therapy for RA with risk of incident dementia.

Methods: Electronic database searches of PubMed, EMBASE and Cochrane Library were performed. Observational studies that assessed the association of dementia with DMARDs in RA were included. Pooled risk ratios (RRs) with 95% CIs were used as summary statistic. The certainty of evidence was judged by using the Grading of Recommendations Assessment, Development and Evaluation system.

Results: Overall, 14 studies involving 940 442 patients with RA were included. Pooled RR for developing dementia was 0.76 (95% CI 0.72 to 0.80) in patients taking biological DMARDs overall versus those taking conventional synthetic DMARDs, with 24% for TNF inhibitors (RR 0.76, 95% CI 0.71 to 0.82), 24% for non-TNF biologics (RR 0.76, 95% CI 0.70 to 0.83), separately. There was a significant subgroup effect among different types of TNF inhibitors (RR 0.58 [95%CI 0.53 to 0.65], 0.65 [95% CI 0.59 to 0.72], 0.80 [95% CI 0.72 to 0.88] for etanercept, adalimumab, infliximab, respectively; p value between groups=0.002). However, compared with non-users of DMARDs or investigative treatment, no significant effect on dementia incidence was observed in those receiving conventional synthetic DMARDs overall (RR 0.84, 95% CI 0.59 to 1.20), methotrexate (RR 0.78, 95% CI 0.54 to 1.12), hydroxychloroquine (RR 0.95, 95% CI 0.63 to 1.44), except for sulfasalazine (RR 1.27, 95% CI 1.06 to 1.50).

Conclusions: Biological DMARDs for RA are associated with decreased dementia risk, while protective effect is not observed in conventional synthetic DMARDs. Controlled clinical trials on TNF inhibitors are necessary to test their neuroprotective potentials.

Keywords: Biological Therapy; Methotrexate; Rheumatoid Arthritis.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Search and selection of observational studies for systematic review and meta-analysis.
Figure 2
Figure 2
Meta-analysis of dementia risk associated with DMARDs in patients with rheumatoid arthritis. csDMARDs, conventional synthetic DMARDs; DMARDs, disease-modifying antirheumatic drugs.
See this image and copyright information in PMC

References

    1. Avan A, Hachinski V. Global, regional, and national trends of dementia incidence and risk factors, 1990-2019: A global burden of disease study. Alzheimers Dement 2023;19:1281–91. 10.1002/alz.12764 - DOI - PubMed
    1. Nichols E, Steinmetz JD, Vollset SE, et al. . Dementia forecasting collaborators. estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the global burden of disease study 2019. The Lancet Public Health 2022;7:e105–25. 10.1016/S2468-2667(21)00249-8 - DOI - PMC - PubMed
    1. Nichols E, Szoeke CEI, Vollset SE, et al. . Dementia collaborators. global, regional, and national burden of Alzheimer’s disease and other Dementias, 1990-2016: a systematic analysis for the global burden of disease study 2016. The Lancet Neurology 2019;18:88–106. 10.1016/S1474-4422(18)30403-4 - DOI - PMC - PubMed
    1. Hendriks S, Peetoom K, Bakker C, et al. . Global incidence of young-onset dementia: a systematic review and meta-analysis. Alzheimers Dement June 17, 2022. 10.1002/alz.12695 - DOI - PubMed
    1. Velandia PP, Miller-Petrie MK, Chen C, et al. . Global and regional spending on dementia care from 2000-2019 and expected future health spending scenarios from 2020-2050: an economic Modelling exercise. EClinicalMedicine 2022;45:101337. 10.1016/j.eclinm.2022.101337 - DOI - PMC - PubMed

MeSH terms

Substances